GH001 Meets Primary Endpoint in Phase 2b TRD Trial
GH Research PLC announced positive Phase 2b trial results for GH001, an inhalable mebufotenin treatment for treatment-resistant depression (TRD)....
GH Research PLC announced positive Phase 2b trial results for GH001, an inhalable mebufotenin treatment for treatment-resistant depression (TRD)....
Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, a monoclonal antibody designed to offer superior, long-lasting protection...
Median Technologies announced positive top-line results from its RELIVE study for eyonis™ LCS, an AI-powered lung cancer screening software....
Researchers found that C2N Diagnostics‘ PrecivityAD2 blood test improved healthcare providers’ ability to assess the likelihood of Alzheimer’s diseaseAlzheimer’s...
Eli Lilly’s Omvoh, an IL-23 inhibitor previously approved for ulcerative colitis, has received FDA approval for Crohn’sCrohn’s disease. Despite...
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has been recommended for approval...
CervoMed provided an update on its Phase 2b RewinD-LB trial for neflamapimod in dementia with Lewy bodies (DLB). The...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Merck’s CAPVAXIVE, a 21-valent...
Eisai and Biogen provided an update on the European Union’s regulatory review of lecanemab, a treatment for early-stage Alzheimer’s...
Rapid Medical has enrolled the first patient in its COGNITIVE study, investigating the link between mechanical thrombectomy using their...